Published in:
27-07-2022 | Prostate Cancer | Research Letter
Influence of Darolutamide on Cabazitaxel Systemic Exposure
Authors:
Stefan A. J. Buck, Niels A. D. Guchelaar, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Esther Oomen-de Hoop, Hans M. Westgeest, Paul Hamberg, Danielle Mathijssen-van Stein, Martijn P. Lolkema, Stijn L. W. Koolen, Ronald de Wit, Ron H. J. Mathijssen
Published in:
Clinical Pharmacokinetics
|
Issue 10/2022
Login to get access
Excerpt
Patients with metastatic prostate cancer currently receive taxane chemotherapy or androgen receptor signalling inhibitors (ARSIs) already in the hormone-sensitive stage. Because of this extensive treatment history, patients with metastatic castration-resistant prostate cancer (mCRPC) are further prone to drug resistance as a result of cross-resistance and clonal evolution of therapy-resistant clones [
1]. The taxane cabazitaxel, reserved for patients with mCRPC after progression on docetaxel, is often perceived as an option of last resort in this population. Therefore, strategies to overcome drug resistance to cabazitaxel are highly desired. …